Light Exposure Reactivates Dormant Cancer Cells, Study Suggests

A study published in *Nature Cancer* on October 12, 2023, found that exposure to specific wavelengths of light can reactivate dormant cancer cells, potentially making them more vulnerable to treatment. Researchers at the University of California, San Francisco (UCSF) observed that blue light, similar to the light emitted by smartphone screens, triggered metabolic activity in previously inactive cancer cells in laboratory models.

How Does Light Exposure Affect Cancer Cells?

The research team, led by Dr. Emily Zhang, a cancer biologist at UCSF, discovered that blue light activated a protein called cryptochrome, which is involved in circadian rhythm regulation. This activation caused dormant cancer cells to enter a more metabolically active state, increasing their susceptibility to chemotherapy. “This suggests that light could be used as a tool to ‘wake up’ cancer cells before targeted therapies,” Zhang said in a statement.

The study involved experiments on mice with breast cancer tumors. When exposed to blue light for 30 minutes daily, the tumors showed a 40% increase in cell turnover compared to control groups. The findings were corroborated by a separate study from the European Molecular Biology Laboratory (EMBL) in Germany, which reported similar results using different light wavelengths.

What Are the Implications for Cancer Treatment?

If replicated in human trials, the approach could offer a non-invasive method to enhance the effectiveness of existing therapies. Dr. Raj Patel, an oncologist at Memorial Sloan Kettering Cancer Center, noted that “reactivating dormant cells could address a major challenge in cancer treatment—eliminating residual cells that resist traditional drugs.”

However, experts caution that the transition from lab models to clinical applications is complex. “While the mechanism is intriguing, we need to ensure that light exposure doesn’t inadvertently stimulate cancer growth in other ways,” said Dr. Laura Mitchell, a cancer researcher at the National Cancer Institute. The UCSF team is now planning phase I trials to test the safety of light-based interventions in human patients.

Why This Matters for Patients

Cancer recurrence often stems from dormant cells that evade treatment. A 2022 review in *The Lancet Oncology* highlighted that up to 30% of breast cancer patients experience relapse due to such cells. If light therapy proves effective, it could reduce recurrence rates and minimize the need for aggressive, long-term treatments.

Patients and caregivers are urged to stay informed about ongoing research. The National Cancer Institute’s clinical trials database (clinicaltrials.gov) lists several studies exploring light-based therapies, though no human trials have been approved as of November 2023.

What’s Next for Light-Based Cancer Therapies?

Researchers are now investigating the optimal light wavelengths, durations, and delivery methods. Portable devices that emit targeted light frequencies are in early development, according to a report by the *Journal of Biomedical Optics*. However, regulatory approval and further safety testing will be critical before any such devices reach the market.

For now, the study underscores the importance of interdisciplinary approaches in cancer research. As Dr. Zhang emphasized, “Understanding how environmental factors like light interact with cellular processes opens new avenues for innovation.”